Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.5 SEK | +2.33% | +11.98% | +1.24% |
Apr. 25 | Transcript : Humana AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
Apr. 25 | Humana AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its low valuation, with P/E ratio at 6.66 and 5.92 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.24% | 124M | B | ||
-24.26% | 2.18B | B- | ||
-1.23% | 1.41B | - | C+ | |
-26.82% | 1.37B | - | ||
+15.23% | 706M | - | B | |
-2.73% | 464M | B- | ||
+240.37% | 432M | - | D+ | |
-7.77% | 322M | - | - | |
+39.04% | 88.82M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HUM Stock
- Ratings Humana AB